新辅助PD-1抑制剂:两个案例的故事
Journal of drugs in dermatology : JDD
|February 2, 2024
概括
新辅助性PD-1抑制剂在治疗晚期皮肤状细胞癌 (cSCC) 和默克尔细胞癌 (MCC) 方面表现有前途. 这种方法可以改善治疗的持续时间,并降低高风险患者的复发风险.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 免疫治疗是一种免疫疗法.
背景情况:
- 局部发达的皮肤状细胞癌 (cSCC) 和默克尔细胞癌 (MCC) 往往治疗结果不佳,复发率高.
- 辅助PD-1抑制剂改善了反应率和持续时间,但并没有降低高风险切除性疾病的复发风险.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


